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Abstract
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by immature granulocytes in
peripheral blood and bone marrow. In 95% of cases, it is always due to the presence of Philadelphia
chromosome characterized by the presence of reciprocal translocation between chromosome 9 and 22.
However, in 7% -17% of individuals, extramedullary proliferation also occurs, either in skin, lymph nodes,
bone or central nervous system (CNS), which could be either myeloid, lymphoid or mixed progenitor in
origin. The present case is of a 23-year-old male who presented with lower limb weakness, bowel and
urinary incontinence. His complete blood count (CBC) findings showed a raised white blood count (WBC) of
408 X 10E9/L. Peripheral film, bone marrow biopsy and immunohistochemistry showed findings consistent
with CML in chronic phase. Bone marrow cytogenetic revealed the presence of Philadelphia chromosome.
Simultaneously, magnetic resonance imaging (MRI) was done which revealed extradural mass at L1-L3 level;
histopathological and immunohistochemistry findings showed features compatible with precursor B cell
lymphoblastic lymphoma. His cerebrospinal fluid (CSF) cytology revealed similar blast cells. This
extramedullary presence of lymphoid blast cells in the CNS put the patient in the rare entity of CML in blast
crisis. He was started on tablet nilotinib and also received multiple cycles of intrathecal chemotherapy with
cytosar, methotrexate and hydrocortisone. He also underwent radiotherapy of extradural mass. His lower
limb weakness improved dramatically. However, after receiving the fourth cycle of intrathecal therapy, the
patient died consequent to neutropenic sepsis. Extramedullary blast crisis in CML has a poor prognosis. Any
patient with CML, presenting with CNS symptoms or lymph node enlargement should be
thoroughly investigated for extramedullary blast crisis, as there is a considerable change in management
and prognosis from the prototype CML in chronic phase.
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Introduction
Extramedullary presentation of chronic myeloid leukemia (CML) in the form of myeloid sarcoma has been
reported in several literature [1,2]. However concomitant presentation of CML in bone marrow along with
the simultaneous presence of precursor B cell lymphoblastic lymphoma in extramedullary tissue site has
rarely been cited. According to 2018, WHO classification, blast crisis of CML is defined as either more than
20% blast cells in blood/bone marrow or extramedullary proliferation of myeloid progenitor cells/ blast cells.
Here, we present a rare manifestation of CML in blast crisis due to the presence of lymphoid blasts in
extradural mass of central nervous system (CNS) along with granulocytic hyperplasia in peripheral blood
and bone marrow.
Case Presentation
A 23-year-old male presented with bilateral limb weakness, urinary and bowel incontinence. Positive
physical examination findings revealed massive splenomegaly, motor power of 1/5 and loss of deep tendon
reflexes in both lower limbs. Laboratory workup revealed hemoglobin of 11.0 G/dL white cell count (WBC) of
408 x 10E9/L and platelet count of 287 x 10E9/L. Peripheral film and bone marrow findings were consistent
with CML in chronic phase (Figure 1, Leishman staining; X400).
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FIGURE 1: Bone marrow smear showing gross granulocytic hyperplasia
Bcr-abl translocation was detected in 95% of nuclei counted by FISH. MRI lumbosacral spine revealed
extradural mass at L1-L3 level; laminectomy was done. Histopathological findings of this extradural mass
showed sheets of small-sized neoplastic cells with scant cytoplasm, round nuclei with coarse chromatin
(Figure 2, hematoxylin and eosin; X200 ). Neoplastic cells were diffuse positive for Tdt and CD79a (Figures
3, 4; paraffin-embedded tissue X200), PAX5 and showed proliferative index of 95%. Cells were negative for
CD3. Based on which findings were consistent with precursor B cell lymphoblastic lymphoma. 
FIGURE 2: Diffuse infiltrate of lymphoid blasts in extradural mass
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FIGURE 3: Neoplastic cells of extradural mass showing positivity for Tdt
 
FIGURE 4: Neoplastic cells of extradural mass showing positivity for
CD79a
His CSF DR showed WBC of 150 cu/mm, and protein of 81 mg/dL. Cytology revealed a large number of
atypical cells with mildly enlarged nuclei, irregular nuclear contour and scanty cytoplasm.
This patient was diagnosed with CML with extramedullary blast crisis, presenting as CNS leukemia. Patient
was started on nilotinib 800mg daily. He received multiple doses of intrathecal chemotherapy with cytosar,
methotrexate and hydrocortisone followed by involved field radiotherapy of extradural mass. There was a
significant improvement in lower limb weakness.
However, the patient was readmitted on third day after receiving fourth dose of triple Intrathecal therapy,
with febrile neutropenia (WBC:0.2) and died after two days due to E-coli sepsis.
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Discussion
CML is the myeloproliferative disorder identified by the unopposed reproduction of the pluripotent myeloid
stem cell [3]. CML has most commonly three stages: CML chronic phase, CML accelerated phase, and CML
blast crisis/extramedullary phase [3]. The extramedullary phase is a relatively uncommon event with an
incidence rate of 3%-7.9% [3]. It happens due to the invasion of blast cells in regions other than bone [4].
Extramedullary blast presentation can be manifested as an appearance of new tumors or enlargements of
lymph nodes [5]. The manifestation of the extramedullary blast phase as a myeloid sarcoma is reported in
the literature [1]. However, the occurrence of Philadelphia chromosome-positive lymphoma is quite rare [6].
Upon search of the PubMed database, we found that there is only one case reported as Philadelphia
chromosome-positive B cell lymphoblastic lymphoma in testicular tissue [7]. Wei et al. found 10 case reports
from 2003 to 2013 with patients having CML with the finding consistent to lymphoma in extramedullary
tissue, which later found to be blast crisis only [6].
Our patient is also another case of simultaneous occurrence B cell lymphoblastic lymphoma in the
paravertebral region and CML.
On review of literature, it is studied that CML is one of the risk factors for the occurrence of other cancers
(solid and hematological) secondary to bcr-abl aberrations [8]. Bcr-abl gene arises due to the translocation
of the gene between long arm of chromosome 9 to chromosome 22. This leads to the Philadelphia
chromosome (the hallmark of CML). Gajendra et al suggested that this bcr-abl aberration has the potential to
give rise to other malignancies due to genetic instability and clonal evolution [8]. Yap et al. proposed the
concept of tumor heterogeneity and sub-clonal evolution and compared this tumor heterogeneity with the
growing tree model [9]. The progenitor founding mutation of the tumor mainly harbors the trunk and is
found in every tumor subclone. Tumor subclone is represented as the branches of the tree. They possess
founding mutation and could also evolve into other somatic aberration which is known as sub-clonal
evolution. which might lead to the rise of another type of tumor. This phenomenon is called sub-clonal
evolution [9]. Anderson in 2011 approved this phenomenon by analyzing ALL cells through FISH and
identifying the recurring genetic mutation in a different subclone of the same patient [10]. Moreover,
immunophenotypic loss or gain of marker which is a part of tumor heterogeneity along with sub-clonal
evolution can give rise to the metastatic subclone which is different from the primary clonal mutation [7].
The exact phenomena happened with our patients. Therefore, in CML patient Bcr-abl gene instability could
rise to other tumor and it is important to have an adequate follow-up in patients for the formation of other
hematological tumors secondary to sub-clonal evolution.
Conclusions
This report suggests that Bcr-abl gene is present in all cases of CML and in 20% of acute lymphoblastic
lymphoma cases may have an important role in the simultaneous presentation of dual pathology in this
patient. Hence it is pivotal to keep an eye and have a regular follow-up to identify any concomitant tumor
formation in the patient.
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